ZURICH (Reuters) - Pfizer Inc is facing criticism, and potential legal action, over its surprise move to temporarily delay COVID-19 vaccine shipments to European countries that fear disruptions could throw their inoculation campaigns into disarray.
British, then U.S. and European approvals of Pfizer and BioNTech's mRNA vaccine late last year prompted celebrations, only to be followed by early-2021 anxiety as the reality sets in that vaccinating billions across the world will be fraught with unforeseen hurdles.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!